124 related articles for article (PubMed ID: 37918263)
1. Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines.
Dhall A; Patiyal S; Kaur H; Raghava GPS
Comput Biol Med; 2023 Dec; 167():107594. PubMed ID: 37918263
[TBL] [Abstract][Full Text] [Related]
2. Computing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical Characteristics.
Dhall A; Patiyal S; Kaur H; Bhalla S; Arora C; Raghava GPS
Front Genet; 2020; 11():221. PubMed ID: 32273881
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
[TBL] [Abstract][Full Text] [Related]
4. Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab.
Takahashi S; Narita S; Fujiyama N; Hatakeyama S; Kobayashi T; Kato R; Naito S; Sakatani T; Kashima S; Koizumi A; Yamamoto R; Nara T; Kanda S; Numakura K; Saito M; Obara W; Tsuchiya N; Ohyama C; Ogawa O; Habuchi T
Cancer Sci; 2022 Dec; 113(12):4059-4069. PubMed ID: 35848083
[TBL] [Abstract][Full Text] [Related]
5. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.
Correale P; Saladino RE; Giannarelli D; Giannicola R; Agostino R; Staropoli N; Strangio A; Del Giudice T; Nardone V; Altomonte M; Pastina P; Tini P; Falzea AC; Imbesi N; Arcati V; Romeo G; Caracciolo D; Luce A; Caraglia M; Giordano A; Pirtoli L; Necas A; Amler E; Barbieri V; Tassone P; Tagliaferri P
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554614
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract][Full Text] [Related]
7. In silico tools and databases for designing cancer immunotherapy.
Dhall A; Jain S; Sharma N; Naorem LD; Kaur D; Patiyal S; Raghava GPS
Adv Protein Chem Struct Biol; 2022; 129():1-50. PubMed ID: 35305716
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer. Human leukocyte antigen II, interleukin-6, and interleukin-6 receptor expression determined by the polymerase chain reaction.
Meyers FJ; Gumerlock PH; Kawasaki ES; Wang AM; deVere White RW; Erlich HA
Cancer; 1991 Apr; 67(8):2087-95. PubMed ID: 2004327
[TBL] [Abstract][Full Text] [Related]
9. LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas.
Maleno I; Romero JM; Cabrera T; Paco L; Aptsiauri N; Cozar JM; Tallada M; López-Nevot MA; Garrido F
Immunogenetics; 2006 Jul; 58(7):503-10. PubMed ID: 16705407
[TBL] [Abstract][Full Text] [Related]
10. Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers.
Guillamón CF; Gimeno L; Server G; Martínez-Sánchez MV; Escudero JF; López-Cubillana P; Cabezas-Herrera J; Campillo JA; Abellan DJ; Martínez-García J; Martínez-Escribano J; Ferri B; López-Álvarez MR; Moreno-Alarcón C; Moya-Quiles MR; Muro M; Minguela A
Eur Urol Oncol; 2021 Apr; 4(2):246-255. PubMed ID: 31411976
[TBL] [Abstract][Full Text] [Related]
11. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
Chen P; Zhao L; Wang H; Zhang L; Zhang W; Zhu J; Yu J; Zhao S; Li W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362829
[TBL] [Abstract][Full Text] [Related]
12. High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder.
Lee YE; Chan TC; Tian YF; Liang PI; Shiue YL; Chen YS; He HL
Urol Oncol; 2019 May; 37(5):299.e7-299.e18. PubMed ID: 30660494
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan.
Nagata Y; Hanagiri T; Mizukami M; Kuroda K; Shigematsu Y; Baba T; Ichiki Y; Yasuda M; So T; Takenoyama M; Sugio K; Nagashima A; Yasumoto K
Lung Cancer; 2009 Jul; 65(1):91-7. PubMed ID: 19054590
[TBL] [Abstract][Full Text] [Related]
14. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
Xu HH; Wang HL; Xing TJ; Wang XQ
Front Immunol; 2022; 13():851622. PubMed ID: 35924232
[TBL] [Abstract][Full Text] [Related]
15. HLAncPred: a method for predicting promiscuous non-classical HLA binding sites.
Dhall A; Patiyal S; Raghava GPS
Brief Bioinform; 2022 Sep; 23(5):. PubMed ID: 35580839
[TBL] [Abstract][Full Text] [Related]
16. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
[TBL] [Abstract][Full Text] [Related]
17. Frequency of Class I and II HLA alleles in patients with lung cancer according to chemotherapy response and 5-year survival.
Araz O; Ucar EY; Meral M; Yalcin A; Acemoglu H; Dogan H; Karaman A; Aydin Y; Gorguner M; Akgun M
Clin Respir J; 2015 Jul; 9(3):297-304. PubMed ID: 24720676
[TBL] [Abstract][Full Text] [Related]
18. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
[TBL] [Abstract][Full Text] [Related]
19. Predicting progression of bladder urothelial carcinoma using microRNA expression.
Rosenberg E; Baniel J; Spector Y; Faerman A; Meiri E; Aharonov R; Margel D; Goren Y; Nativ O
BJU Int; 2013 Nov; 112(7):1027-34. PubMed ID: 23387295
[TBL] [Abstract][Full Text] [Related]
20. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
